Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That' ...

To help you in your search, three Fool.com contributors have pulled together reports on a few opportunities they think are ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

DelveInsight's Respiratory Disease Testing Market Insights report provides the current and forecast market analysis, individual ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The largest 25 pharmaceutical companies, based on 2013 total revenue, that were included in the study sample were: Abbott Laboratories; AbbVie; Actavis; Allergan; Amgen; Astellas; AstraZeneca (AZ ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

dividend-frequency { font-size: 12px; color: #6c757d; } Through a meticulous analysis of AbbVie, we can observe the following trends: A Price to Earnings ratio of 70.21 significantly below the ...

The neurological biomarkers market is expanding as neurological disorders, including dementia and Parkinson's disease, become more prevalent with an aging global population. Innovations in biomarker ...